This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story | The Motley Fool
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Source: The Motley Fool
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.